Edgar Engleman
Co-Director, Tumor Immunology and Immunotherapy, Stanford Cancer Institute · Stanford Health Care
Credentials: · ·
History
- Present
Tumor Immunology and Immunotherapy · Stanford Health Care
- Present
Stanford Blood Center · Stanford Health Care
- Present
Stanford Blood Center · Stanford Health Care
Pathology-Anatomic and Clinical
Research
Review · Annual review of pathology · 2021 · Last of 3 authors · Corresponding · 1,792 citations
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
Case report · Nature Medicine · 1996 · 1,567 citations
Normalization of obesity-associated insulin resistance through immunotherapy
Nature Medicine · 2009 · 1,141 citations
- SS
28 papers · 6 as a fellow
- FG
16 papers
14 papers · 3 as a fellow
11 papers
11 papers · 4 as a resident
10 papers
8 papers
8 papers · 1 as a resident
Grants
- 2021–2031
Targeting Lymph Node Dependent Immune Tolerance in Cancer
National Cancer Institute · R01
Contact PI · $3.2M · Stanford University
- 2026–2031
Induction of Acquired Fetal Tolerance Through an EPO-Dependent Pathway
National Institute of Allergy and Infectious Diseases · R01
PI · $782.7K · Stanford University
- 2026–2031
The Role of Tolerogenic Macrophages in Tumor Metastasis
National Cancer Institute · R01
Contact PI · $550.9K · Stanford University
- 2023–2028
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression
National Cancer Institute · U54
PI · $7.6M · Stanford University
Clinical trials
- 2005–2008
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
Principal investigator · Completed · Phase 1
George Albert Fisher
- 2004–2007
Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Principal investigator · Terminated · Phase 1
Stanford University